1. Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine kinase inhibitor treatment stratified into predefined age categories: ≤50, 51–60, 61–70, 71–80 and >80 ...
Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine kinase inhibitor treatment stratified into predefined age categories: ≤50, 51–60, 61–70, 71–80 and >80 years. The difference was statistically significant (p<0.001, log-rank test).
Shang-Gin Wu et al. ERJ Open Res 2017;3:
©2017 by European Respiratory Society